| アブストラクト | Uncontrolled blood pressure (BP) and therapeutic inertia pose significant challenges in effectively managing hypertension. This study objective was to quantify levels of uncontrolled BP and therapeutic inertia among patients treated for hypertension in primary care. This retrospective cohort study used data recorded by general practitioners from the UK Clinical Practice Research Datalink database. Adults with primary hypertension who received a recorded prescription for any antihypertensive drug between January 2015 and June 2017 (index date) were included, with a follow-up of 18 months. Primary outcomes included the percentage of patients with uncontrolled BP (defined as systolic BP >/=140 mmHg or diastolic BP >/=90 mmHg) and of apparent therapeutic inertia (defined as two consecutive uncontrolled BP records without treatment change) during follow-up. Finally, of 581 260 patients receiving antihypertensive drug(s), 37.2% (n = 216 014) had uncontrolled BP at the index date and 30.3% (n = 175 955) had no record of BP at this date. During follow-up, 59.2% had >/=1 record of uncontrolled BP, in 22% all records showed uncontrolled BP, and 12.8% had no record of BP. Among those with uncontrolled BP at the index date, 72.9% had >/=1 record of uncontrolled BP during follow-up, and in 28.3% all records showed uncontrolled BP. Therapeutic inertia was observed in 33.1% of patients overall, and in 55.7% of those with uncontrolled BP at the index date. In conclusion, BP recording was infrequent, possibly reflecting both a low frequency of measurement and potential under-recording. Uncontrolled BP and therapeutic inertia appear to be widespread in UK general practice. |
|---|
| ジャーナル名 | Journal of clinical hypertension (Greenwich, Conn.) |
|---|
| Pubmed追加日 | 2023/9/23 |
|---|
| 投稿者 | Darricarrere, Celine; Jacquot, Emmanuelle; Bricout, Stephanie; Louis, Caroline; Benard, Marc; Poulter, Neil R |
|---|
| 組織名 | Pharmacoepidemiology and Real World Evidence Department, Servier Laboratories,;Suresnes, France.;Cardiovascular & Metabolic Diseases Therapeutic Area & Life Cycle Management,;Servier Laboratories, Suresnes, France.;Aixial, Boulogne Billancourt, France.;Imperial Clinical Trials Unit, Imperial College London, London, UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37740433/ |
|---|
